Targeting BTN3A1 in vivo using CTX-2026, a unique fully human aglycosylated monoclonal antibody delayed the progression of ovarian cancer in both syngenic and xenograft models through the elicitation of more robust αβ T cell responses. This evidence concerns the gene BTN3A1 and ovarian cancer.